Central vision preservation with modern anti-VEGF therapy.
AMD is the leading cause of central vision loss above 60. Wet AMD responds dramatically to timely intravitreal anti-VEGF therapy.
Dry vs wet AMD
Dry AMD is slowly progressive and managed with AREDS-2 supplements, smoking cessation and monitoring. Wet AMD — where abnormal blood vessels leak under the macula — needs urgent anti-VEGF treatment to halt vision loss.